Older Adult clinical trials

Explore recruiting older adult clinical trials.

Recruiting older adult studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Older Adult trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter, open, prospective, randomized, parallel-group, 12-month trial of REduced immunosuppression for oLdEr AdultS kidnEy transplant recipients: the RELEASE study.

Spain

Therapeutic use (Phase IV) EU CTIS Study details

A randomized, placebo controlled, observer-blind, phase IV pragmatic trial to evaluate the effect of Recombinant Zoster Vaccine (Shingrix®) on incident dementia diagnosis in an older adult population aged ≥76 years in Finland

Finland

Therapeutic use (Phase IV) EU CTIS Study details

Induction therapy with bortezomib, melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) vs. carfilzomib, lenalidomide and dexamethasone (KRd) with/without daratumumab, 18 cycles, followed by consolidation and maintenance with lenalidomide and daratumumab: a phase III, multicenter, randomized clinical trial for older adult patients between 65 and 80 years old, in good general health with newly-diagnosed multiple myeloma

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 60 years and older.

Spain, Belgium, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Older Adult trials by city

Older Adult in Toronto Older Adult in Vancouver Older Adult in Montreal Older Adult in Calgary Older Adult in Edmonton Older Adult in Ottawa Older Adult in Winnipeg Older Adult in Quebec City Older Adult in Hamilton Older Adult in Kitchener Older Adult in London Older Adult in Halifax Older Adult in New York Older Adult in Los Angeles Older Adult in Chicago Older Adult in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease